KOSDAQBiotech & Pharma476060

Onconic Therapeutics

₩10,430▼ 0.67%2026-11-18 close
Market Cap
₩473.6B
Turnover
₩2B
Volume
190K
Shares out.
45.4M
PER
55.4×
PBR
7.0×
EPS
₩227
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Jacubo Sales Growth Meets a Threefold R&D Surge and a Q3 Operating Loss

Prescription growth for the in-house drug Jacubo lifted cumulative sales for the first three quarters of 2026 by 70.3% year on year, but R&D spending rose 3.4 times and pushed the third quarter into an operating loss.

  1. 1

    Annual sales in 2025 were KRW 53.4 billion, up 259.8% from the prior year and the largest of the 2023-2025 period, and operating profit of KRW 12.6 billion marked a return to profit.

  2. 2

    Third-quarter 2026 sales fell to KRW 17 billion, down 11.4% year on year, and the company posted an operating loss of KRW 4.35 billion, a swing from profit a year earlier. The loss attributable to controlling shareholders was KRW 7.69 billion.

  3. 3

    Cumulative R&D spending for the first three quarters of 2026 reached KRW 20.7 billion, about 3.4 times the KRW 6.1 billion a year earlier, according to the company's announcement.

  4. 4

    According to the pharmaceutical market research firm UBIST, Jacubo's third-quarter 2026 outpatient prescription value was KRW 28.75 billion, up 109.6% year on year.

  5. 5

    Nesuparib is in clinical development across four cancer types, and Jacubo had technology export and supply agreements with 27 countries as of June 2026 press reports.

02

Business structure

Onconic Therapeutics (Onconic Therapeutics) is a drug development company established in May 2020 that aims to sell its own drugs to secure revenue and then reinvest that cash into follow-on pipeline programs.

Its main product is Jacubo, a treatment for gastroesophageal reflux disease that the company describes as Korea's 37th domestically developed new drug, launched in Korea in October 2024 and now expanding into gastric ulcer indications. A Phase 3 trial to secure an additional indication is ongoing.

According to BusinessWatch, cumulative third-quarter 2026 Jacubo product sales reached KRW 60.1 billion, up 109% from KRW 28.7 billion a year earlier, and product sales are tallied separately from technology transfer income.

As of June 2026 press reports, the company had technology export and supply agreements covering 27 countries, and Phase 3 trials in China and India have been completed with approval procedures under way.

A recent mission in Mexico involved a marketing approval application, alongside a license and supply deal in Indonesia that extends reach into Latin America and Southeast Asia.

The anticancer pipeline centers on Nesuparib, a dual-target inhibitor, with clinical development in pancreatic, endometrial, ovarian and gastric cancers. The new pipeline program OCN-501 is a candidate intended to reduce muscle loss during weight reduction when combined with GLP-1 class obesity drugs. Because sales are concentrated in one product, prescription trends drive quarterly results.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩19.2B₩8.3B43.3%
2025Q4₩15.6B₩1.6B10.3%
2026Q1₩23B₩4.6B20.0%
2026Q2₩24.4B₩2.8B11.4%
2026Q3₩17B-₩4.3B−25.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩21.1B₩2.2B₩1.7B10.6%—−290.7%
2024₩14.8B-₩4.8B-₩8.1B−32.3%−14.4%8.7%
2025₩53.4B₩12.6B₩15.8B23.6%21.9%5.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

Annual sales were KRW 21.1 billion in 2023, KRW 14.8 billion in 2024 (down 29.5% year on year) and KRW 53.4 billion in 2025 (up 259.8% year on year), making 2025 the largest year and 2024 the smallest within 2023-2025.

Operating profit went from KRW 2.23 billion in 2023 to an operating loss of KRW 4.8 billion in 2024, a swing to a loss, before returning to operating profit of KRW 12.6 billion in 2025. The operating margin was 10.6% in 2023, -32.3% in 2024 and 23.6% in 2025.

Profit attributable to controlling shareholders was KRW 1.68 billion in 2023, a loss of KRW 8.09 billion in 2024 (a swing to a loss), and KRW 15.8 billion in 2025. Net profit including non-controlling interests was reported as KRW 1.68 billion, a net loss of KRW 8.09 billion and KRW 15.8 billion in the same years.

At the end of 2025, total equity was KRW 72 billion, all of it attributable to controlling shareholders, total liabilities were KRW 3.67 billion, and the debt ratio was 5.1%. Operating cash flow was KRW 4.15 billion in 2023, -KRW 7.84 billion in 2024 and KRW 11.4 billion in 2025.

On a quarterly basis, sales of KRW 19.2 billion and operating profit of KRW 8.32 billion in the third quarter of 2025 were followed by sales of KRW 15.6 billion (down 18.9% from the prior quarter) and operating profit of KRW 1.61 billion in the fourth quarter.

Sales rebounded to KRW 23 billion in the first quarter of 2026 (up 47.5% from the prior quarter) with operating profit of KRW 4.59 billion. In the second quarter of 2026, sales were KRW 24.4 billion and operating profit KRW 2.79 billion.

Third-quarter 2026 sales were KRW 17 billion (down 11.4% year on year), with an operating loss of KRW 4.35 billion, a swing from profit a year earlier.

The company attributed the sales decline to lower production during summer holidays and the operating loss to higher R&D spending from new pipeline research and expanded clinical trials at home and abroad.

According to BusinessWatch, cumulative R&D spending for the first three quarters of 2026 was KRW 20.7 billion, about 3.4 times the KRW 6.1 billion a year earlier, and the R&D-to-sales ratio rose from 16% to 32%.

The third-quarter loss attributable to controlling shareholders of KRW 7.69 billion was larger than the operating loss, which press reports tie to a foreign currency translation loss on dollar-denominated assets.

The company's investor materials say a Chinese partner's milestone was booked in the first quarter of 2025, so annual results include one-time contract income. Profit trends depend on whether Jacubo's prescription growth can absorb the expansion in R&D, and they should be read alongside the quarterly pattern.

05

Industry analysis

In the reflux disease treatment market where Jacubo competes, prescription trends directly determine revenue.

According to UBIST, Jacubo's third-quarter 2026 outpatient prescription value was KRW 28.75 billion, up 109.6% year on year, and its monthly prescription value in October 2026 was KRW 10.27 billion, passing KRW 10 billion for the first time two years after launch.

Because prescription growth and company revenue growth move together, whether that growth continues and how share shifts against competing products are the key industry variables.

In oncology, competition among late-stage dual-target anticancer drugs is central, and in a Phase 1b study in metastatic pancreatic cancer, Nesuparib produced complete responses with long-term remission lasting more than 40 months in some patients.

A Phase 1b study involves a small patient population at an early stage, so whether later trials reproduce these results is the key test. In obesity, the company presents OCN-501 as a candidate designed to be combined with GLP-1 class obesity drugs to reduce muscle loss during weight reduction.

In terms of cycle position, the company is moving from commercializing its own product to a phase of sharply higher R&D investment, as the R&D-to-sales ratio rising to 32% in the first three quarters of 2026 shows.

On regulation, approval procedures in China and India and a marketing application in Mexico are in progress, and preparations for FDA pre-IND consultation are under way for entry into U.S. clinical trials.

Compared with other listed Korean biopharma companies, the company's stated distinction is pairing R&D with revenue from its own product.

06

Outlook

The company has said it plans to expand global clinical development of its new pipeline and overseas market entry further in 2027.

Jacubo's Phase 3 trial for an additional indication is ongoing, and the outcomes of approval procedures in China and India and the review of the Mexican application are the next checkpoints for overseas revenue.

Nesuparib is in clinical development across four cancer types, and preparations include FDA pre-IND consultation and production of clinical supplies for entry into U.S. trials.

In June 2026 press reports, the company said it would attend BIO USA 2026, the large biotechnology industry event, to discuss global partnering for Nesuparib.

OCN-501 was reported as selected for an oral presentation after being accepted as a late-breaking abstract at ObesityWeek 2026 of the American Society for the Study of Obesity.

Whether Jacubo's growth continues depends on prescription trends after monthly prescriptions passed KRW 10 billion and on progress in overseas approvals.

R&D spending was KRW 10.1 billion in the third quarter of 2026 alone, more than five times the KRW 1.9 billion a year earlier, and how this spending level flows into 2027 results is the central question of the outlook.

Technology transfer contracts add revenue volatility while also serving as a route for overseas expansion. The next checkpoints are the operating margin in the 2026 annual report and the R&D trend in the first-quarter 2027 report.

07

Valuation

PER
55.4×
PBR
7.0×
ROE
9.7%
EPS
₩227
BPS
₩1,803
Dividend per share
₩0

The price-to-earnings multiple is measured against profit attributable to controlling shareholders over the last four quarters, which totaled KRW 7.16 billion, so with a small earnings base the multiple moves sharply as profit changes. The price-to-book multiple sits in a range with a large premium to net assets.

Total equity grew to KRW 72 billion at the end of 2025, yet market capitalization sits well above that base, and the gap is generally read as expectations for Jacubo's growth and the value of the pipeline. The company pays no dividend, so returns to holders depend on share price movement.

Earnings recovered from a loss in 2024 to profit in 2025, but the third quarter of 2026 returned to an operating loss, so how the multiple is read shifts with quarterly results.

The key variables for valuation are whether R&D spending outpaces revenue growth and how the Nesuparib and Jacubo overseas agreements are reflected in the earnings structure.

Comparing multiples with other listed companies is more accurate when pipeline stage is considered alongside earnings-based metrics, because stages differ widely.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Continued Jacubo prescription growth

According to UBIST, Jacubo's third-quarter 2026 outpatient prescription value rose 109.6% year on year. Monthly prescriptions in October 2026 passed KRW 10 billion for the first time two years after launch. If the growth continues, a wider sales base could show up in reported results.

Expanding anticancer pipeline

Nesuparib is in clinical development across pancreatic, endometrial, ovarian and gastric cancers. A Phase 1b study in metastatic pancreatic cancer presented at ASCO 2026 included a complete responder with remission lasting more than 40 months. Preparations for FDA pre-IND consultation for U.S. trials are expanding the pipeline's reach.

Wider overseas approvals and deals

As of June 2026 press reports, Jacubo had technology export and supply agreements in 27 countries, and approval procedures are under way in China and India after Phase 3 trials were completed. A Mexican application and an Indonesian license and supply deal extend reach into Latin America and Southeast Asia. In quarters when contract income is booked, the sales base could widen further.

09

Bear factors

Q3 swing to loss and R&D burden

The third-quarter 2026 operating loss of KRW 4.35 billion was a swing from profit a year earlier. Third-quarter R&D spending alone reached KRW 10.1 billion, more than five times the KRW 1.9 billion of a year earlier. If R&D expansion keeps outpacing revenue growth, quarterly losses could persist.

Dependence on a single product

Press reports put cumulative Jacubo product sales at KRW 60.1 billion, the bulk of cumulative revenue of KRW 64.4 billion over the same period. Third-quarter sales fell to KRW 17 billion as summer holidays reduced production. Quarterly results can swing sharply with one product's prescriptions and production schedule.

Earnings volatility and a high multiple

Profit attributable to controlling shareholders over the last four quarters totaled KRW 7.16 billion, a thin earnings base. The price-to-book multiple sits in a range with a large premium to net assets.

The company had a loss in 2024, so whether profit has recovered on a stable basis depends on additional quarterly results.

10

Risk factors

Clinical and approval risk

The long-term remission cases for Nesuparib come from Phase 1b data on a small number of patients. If the Phase 3 trial for an additional Jacubo indication or the approval outcomes in China and India are delayed or unfavorable, overseas revenue plans could slip. Oncology drugs often produce different results in later trial stages, so outcomes cannot be assumed.

R&D burden and cash flow

Cumulative R&D spending for the first three quarters of 2026 was KRW 20.7 billion, about 3.4 times a year earlier, and its share of sales rose to 32%. Operating cash flow was -KRW 7.84 billion in 2024 and recovered to KRW 11.4 billion in 2025. If clinical expansion continues, cash flow management becomes another variable for reported results.

FX losses and one-time contract income

Press reports say the third-quarter net loss reflected a foreign currency translation loss on dollar-denominated assets. A Chinese partner's milestone was booked in the first quarter of 2025, and technology transfer income is recorded separately from product sales.

One-time contract income and currency moves can shift quarterly earnings, so the gap between operating results and net profit should be read together.

11

What to watch next

  1. Late March 2027

    Filing of the 2026 annual report. Full-year 2026 sales, operating margin and total R&D spending will be fixed, showing how the R&D expansion through the third quarter of 2026 settles on an annual basis.

  2. Mid-May 2027

    First-quarter 2027 report. Checks whether the R&D spending level holds, whether Jacubo's prescription growth and product sales continue, and whether the gap between operating and net results repeats.

  3. After November 2026 · timing not set

    Outcomes of Jacubo's approval procedures in China and India and the Mexican application review. Approvals would change the structure of overseas sales and technology transfer income.

  4. During 2027 · timing not set

    Results of FDA pre-IND consultation for entry into U.S. trials and interim data from the four-cancer clinical program. These will indicate how far global clinical expansion and new indications can go.

12

Overall view

Onconic Therapeutics has built its sales base on the prescription growth of its in-house drug Jacubo. Annual sales were KRW 53.4 billion in 2025, up 259.8% year on year, and operating profit of KRW 12.6 billion marked a return to profit.

In the third quarter of 2026, however, higher R&D spending and lower production during summer holidays combined to produce an operating loss of KRW 4.35 billion, a swing from profit a year earlier. Cumulative R&D for the first three quarters of 2026 was KRW 20.7 billion, about 3.4 times the year-earlier level.

Supporting factors include Jacubo's prescription growth, with third-quarter outpatient prescription value up 109.6% year on year, Nesuparib's four-cancer clinical program, and technology export deals covering 27 countries.

Offsetting factors include the quarterly swing to a loss, reliance on one product, and a thin earnings base, with profit attributable to controlling shareholders totaling KRW 7.16 billion over the last four quarters. Valuation reflects a large premium to net assets alongside a small earnings base.

The next checkpoints are the operating margin in the 2026 annual report and the R&D trend in the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 12 more articles and sources
  1. thevc.kr
  2. view.asiae.co.kr
  3. ebn.co.kr
  4. medicaldaily.co.kr
  5. incruit.com
  6. m.sedaily.com
  7. kind.krx.co.kr
  8. insightkorea.co.kr
  9. sentv.co.kr
  10. news.bizwatch.co.kr
  11. dailian.co.kr
  12. news.nate.com

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis